Pneumococcal vaccine development.
A 7-valent pneumococcal conjugate vaccine has demonstrated an impact on pneumococcal bacteremia in the immunized pediatric population, extending to nonimmunized adults via herd immunity. A considerable reduction of all-cause pediatric pneumonia has also been found. The impact on all-cause pediatric otitis is limited, but postlicensure data suggests stronger reductions. Higher valency conjugate vaccines are now under development (11V or more). Licensed 23-valent pneumococcal polysaccharide vaccines have been available since 1983 with a demonstrated impact on adult pneumococcal bacteremia. The burden of adult nonbacteremic pneumococcal pneumonia has remained high and efforts to develop improved adult pneumococcal vaccines have been initiated that include conjugates and pneumococcal proteins.
Poolman
Jan T
JT
R & D Bacterial Vaccine Programme, GlaxoSmithKline Biologicals, Rue de l'Institut, 89 1330 Rixensart, Belgium. jan.poolman@gskbio.com
D000328:Adult; D000367:Age Factors; D000368:Aged; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology; D002675:Child, Preschool; D015195:Drug Design; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D011018:Pneumonia, Pneumococcal / Q000276:immunology / Q000517:prevention & control*; D011358:Product Surveillance, Postmarketing; D016032:Randomized Controlled Trials as Topic; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination / Q000639:trends*; D018074:Vaccines, Conjugate
C414006:23-valent pneumococcal capsular polysaccharide vaccine; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate; C051592:pneumococcal surface protein A